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Mitochondrial production of reactive oxygen species
(ROS) affects many processes in health and disease.
SPG7 assembles with AFG3L2 into the mAAA
protease at the inner membrane of mitochondria,
degrades damaged proteins, and regulates the syn-
thesis of mitochondrial ribosomes. SPG7 is cleaved
and activated by AFG3L2 upon assembly. A variant
in SPG7 that replaces arginine 688 with glutamine
(Q688) is associated with several phenotypes, in-
cluding toxicity of chemotherapeutic agents, type 2
diabetes mellitus, and (as reported here) coronary
artery disease. We demonstrate that SPG7 process-
ing is regulated by tyrosine phosphorylation of
AFG3L2. Carriers of Q688 bypass this regulation
and constitutively process and activate SPG7
mAAA protease. Cells expressing Q688 produce
higher ATP levels and ROS, promoting cell prolifera-
tion. Our results thus reveal an unexpected link
between the phosphorylation-dependent regulation
of the mitochondria mAAA protease affecting ROS
production and several clinical phenotypes.
INTRODUCTION
Chronic diseases, like type 2 diabetes mellitus (T2DM) or coro-
nary artery disease (CAD), are associated with altered mitochon-
drial function and elevated reactive oxygen species (ROS)
production (Lowell and Shulman, 2005; Madamanchi and
Runge, 2007). Mitochondria provide energy (ATP) to the cell834 Cell Reports 7, 834–847, May 8, 2014 ª2014 The Authorsthrough oxidative metabolism at the electron transport chain
(ETC). During this process, mitochondria also produce ROS as
a by-product. ROS oxidize and damage mitochondrial proteins
and DNA. For this reason, mitochondria contain enzymes that
eliminate ROS, including superoxide dismutase 2 (SOD2) and
peroxiredoxin 3 (Prdx3), to actively maintain a reduced state
and the mitochondrial electrochemical potential required for
ATP production (Hansen et al., 2006).
Mitochondrial matrix proteins that are damaged from oxida-
tion by ROS are degraded by the Lon protease (Bota and Davies,
2002). In addition, the mAAA (matrix ATPase associated with
diverse cellular activities) protease also participates in this pro-
cess because oxidized mitochondrial proteins accumulate in
brain extracts from mice carrying a missense mutation in the
core AAA domain of AFG3L2 or inmice deficient in AFG3L2 (Mal-
tecca and Casari, 2010). By sensing and destroying damaged
matrix proteins, including the components of the ETC, the
mAAA protease performs an essential quality control function
(Arlt et al., 1996; Hornig-Do et al., 2012). The mAAA protease
also regulates the assembly of mitochondrial ribosomes and
the synthesis of respiratory chain subunits within mitochondria
(Almajan et al., 2012; Nolden et al., 2005). Thus, by controlling
the integrity and assembly of the ETC, the mAAA protease may
be uniquely positioned to regulate ROS production. Recent
evidence indicates that mitochondrial ROS (mROS) production
is actively regulated (Sena and Chandel, 2012) and controls
diverse mechanisms such as cell proliferation (Formentini
et al., 2012) and the bactericidal activity of macrophages (West
et al., 2011).
The mAAA protease is assembled as a homohexamer of
AFG3L2 or as a heterohexamer between SPG7 and AFG3L2
(Koppen et al., 2007). AFG3L2 is a self-processing protease
that is active upon assembly at the mitochondrial inner
membrane. In contrast, cleavage and processing of SPG7 to
a mature active protease require coassembly with AFG3L2
(Koppen et al., 2009). Loss-of-function mutations in AFG3L2
cause spinocerebellar and spastic ataxia (Di Bella et al., 2010;
Pierson et al., 2011). Mutations in SPG7 (also called paraplegin)
cause hereditary spastic paraplegia (HSP), a neurodegenerative
disorder characterized by progressive weakness and spasticity
of the lower limbs due to degeneration of corticospinal axons
(Atorino et al., 2003; Casari et al., 1998). Of note, vascular lesions
in the frontal cortex have been detected by functional MRI in
some forms of HSP linked to the SPG7 locus (De Michele
et al., 1998).
A protein-coding variant that changes an arginine (R688) to
glutamine (Q688) in the highly conserved protease domain of
SPG7 was recently associated with resistance to the toxic
effects of anticancer drugs (Deeken et al., 2010). This same
variant has also been reported to nominally associate with
the risk for T2DM (Morris et al., 2012). Here, we report an
association of this variant with risk for CAD. Our study revealed
that unlike the common form of SPG7 whose cleavage is
regulated, the Q688 variant is constitutively cleaved and acti-
vated. The Q688 variant rescued a dominant-negative form of
AFG3L2. Moreover, the Q688 SPG7 variant increased ROS
production, promoting cell proliferation and lowering endothe-
lial nitric oxide bioactivity. Our study provides a regulatory
mechanism linking mitochondrial matrix quality control to
mROS production.
RESULTS
A Variant of SPG7, Q688, Is Associated with CAD Risk
In a search for protein-coding variants that associate with the
risk for CAD, we identified one variant (rs12960) in SPG7 in
the Ottawa Heart Genomics Study (OHGS) genome-wide
association study (GWAS): 1,542 cases and 1,455 controls
(p = 2.34 3 103), odds ratio (OR) (95% confidence interval
[CI]) = 1.235 (1.078–1.415). Carrying this allele forward by
meta-analysis of 12 GWASs in the CARDIoGRAM consortium
comprising 22,233 CAD cases and 64,764 controls, a consistent
suggestive association with CAD was found with a combined
association of p = 3.74 3 105, OR (95% CI) = 1.076 (1.039–
1.114) (Figures 1A and 1B). This variant replaces a positively
charged arginine at position 688 with a neutral glutamine resi-
due (Figure 1C) and occurs at an allele frequency of 13%–
15% in the European population. It is noteworthy that R688 is
invariant among vertebrates and is not polymorphic in the
mouse. Although the Q688 allele did not reach genome-wide
significant association with CAD in our study, a survey of the
literature showed that this allele is associated with other clini-
cally important phenotypes, including resistance to the chemo-
therapeutic agent docetaxel (Deeken et al., 2010) and T2DM
(Morris et al., 2012). Given the pleiotropic effects of this allele,
we pursued its functional characterization.
SPG7 Protein Processing and Maturation Are Enhanced
in Individuals Who Carry the Q688 Allele
SPG7, like AFG3L2, undergoes two maturation steps. Upon
import into the mitochondrial matrix, the N-terminal signal pep-tide is cleaved by the mitochondrial-processing peptidase
(MPP) (Koppen et al., 2009). A second proteolytic cleavage re-
moves an additional N-terminal fragment upon assembly of
SPG7 into the SPG7/AFG3L2 heterohexamer (Koppen et al.,
2009).Whereas AFG3L2 is autocatalytic, removing its ownN-ter-
minal intermediate peptide, SPG7 is dependent on AFG3L2 to be
processed to its mature form. Because SPG7 processing is
necessary to activate its protease activity, we examined the
pattern of SPG7 processing by immunoblot analysis of periph-
eral blood mononuclear cells (PBMCs) from genotyped CAD pa-
tients. Processing of the SPG7 protein to its shorter mature and
proteolytically active form was highly correlated (p = 1.233 107
by trend test) with the gene dosage of the Q688 variant; with
nearly 90% of SPG7 being fully processed in PBMCs of patients
homozygous for Q688 (Figures 1D and 1E). In addition to being
readily accessible from our GWAS-banked blood samples,
PBMCs are relevant for CAD studies because they give rise to
macrophages, the inflammatory cells that accumulate choles-
terol to become the foam cells of atherosclerotic lesions (Ross,
1999). In addition, several studies have validated changes in
PBMC gene expression as sensitive indicators of CAD progres-
sion or myocardial infarction (Kiliszek et al., 2012; Wingrove
et al., 2008). Although the precise location of the N-terminal
cleavage sites has been determined for mouse SPG7 (Koppen
et al., 2009), it has not been identified in human SPG7 whose
N-terminal sequence is divergent from the mouse. Thus, we
assigned the names ‘‘precursor,’’ ‘‘intermediate,’’ and ‘‘mature’’
based on the molecular weights of the bands in the immunoblot.
Migration and proliferation of arterial smooth muscle cells
enlarge the atherosclerotic lesion (Ross, 1999). We obtained pri-
mary cultures of human aortic smooth muscle cells (HAoSMCs)
from different individuals and found the same correlation with
increased processing of SPG7 in the two samples heterozygote
for the Q688 variant (Figure 1F). These results show that the
Q688 variant is associated with increased processing of SPG7
to its proteolytically active form.
Stable HEK293 Cells Expressing the Q688 SPG7 Variant
Also Show Increased SPG7 Maturation
To verify that processing of the Q688 variant is intrinsic to this
isoform and to further functionally characterize the Q688 variant,
human embryonic kidney 293 (HEK293) cells were stably trans-
fected with lentiviral vectors expressing equal levels of the
common R688 allele of SPG7 or the CAD risk variant Q688
(Figures 1G and S1). We chose HEK293 cells because they are
easily transfected human cells homozygous for the common
allele of SPG7. Isolated mitochondria showed that overexpres-
sion of the common form of SPG7 did not affect its processing,
whereas overexpression of the Q688 variant markedly increased
processing to the mature SPG7. Small hairpin RNA (shRNA)
knockdown of SPG7 confirmed the identity of the bands as
SPG7 (Figure S2). That SPG7 is largely unprocessed in untrans-
fected HEK293 cells was noted (Figure 1G). We cannot exclude
the possibility that the intermediate band is a partially processed
fragment and that further N-terminal cleavage occurs. Nonethe-
less, these cells replicate the phenotype (i.e., increased SPG7
processing) observed in PBMCs and HAoSMCs that carry the
Q688 allele. This result indicates that increased processing ofCell Reports 7, 834–847, May 8, 2014 ª2014 The Authors 835
Figure 1. Q688 Variant of SPG7 Is Associated with Risk for CAD and Alters Proteolytic Processing of SPG7
(A) Cluster of linked SNPs at the SPG7 gene genotyped in CARDIoGRAM (Schunkert et al., 2011).
(B) Meta-analysis of 12 GWASs combining genotype and imputed SNP data from over 22,000 CAD cases and 60,000 controls suggests that the SPG7 locus is
associated with CAD (p = 3.74 3 105; heterogeneity, I2 = 0).
(C) SNP rs12960 replaces the conserved arginine 688 (R688) with glutamine.
(D) PBMCs from patients with CAD genotyped for rs12960 reveal increased proteolytic processing of SPG7 in Q688 homozygotes (QQ) compared to R688
homozygotes (RR) in whole-cell extracts. Note the increased processing from the precursor (p) and intermediate (i) forms to the mature form (m) in a repre-
sentative blot.
(E) Quantification of immunoblots, normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels, reveals an allele dosage association with the
processing of SPG7. RR, (n = 14), RQ, heterozygotes (n = 4), and QQ, homozygotes for the Q688 allele (n = 9).
(F) HAoSMCs genotyped for rs12960 also reveal increased processing to mature SPG7 in heterozygotes (RQ) compared to homozygotes for the common allele
(RR) in whole-cell extracts. The identifier for each donor is simplified to the last two digits (see Experimental Procedures for details).
(legend continued on next page)
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Q688SPG7 variant is not due to overexpression or to an extrinsic
factor. It is noteworthy that AFG3L2 levels were elevated in cells
expressing the Q688 variant but not the common form of SPG7,
suggesting that the Q688 variant might stabilize AFG3L2 in the
heterohexameric complex. Also of note, Q688 cells had elevated
levels of PRDX3, a mitochondrial antioxidant protein that scav-
enges ROS (Araki et al., 1999).
The Q688 Form of SPG7 Is a Gain-of-Function Variant
Processing of SPG7 to its mature form requires AFG3L2. There-
fore, we asked what effect silencing AFG3L2 would have on pro-
cessing of the common and Q688 variant of SPG7. HEK293 cells
expressing the common form of SPG7 accumulated unpro-
cessed protein with AFG3L2 silencing, as expected (Figure 2A).
Surprisingly, Q688 was more efficiently processed even when
AFG3L2 was knocked down.
Because the SPG7 Q688 variant is more readily processed
to its proteolytically active mature form, we used a yeast
complementation assay to test whether the Q688 variant could
rescue a functionally inactive mutant of AFG3L2. A dominant-
negative mutant of AFG3L2 (E691K) that causes spinocerebel-
lar ataxia 28 (SCA28) does not allow mAAA-deficient yeast
(lacking both the SPG7 and AFG3L2 homologs) to grow on a
nonfermentable carbon source (glycerol) that requires mito-
chondrial function (Di Bella et al., 2010). This mutant was not
rescued by the common form of SPG7 (Di Bella et al., 2010;
and also see Figure 2B). Strikingly, growth arrest caused by
the AFG3L2 (E691K) mutation was fully rescued by the Q688
SPG7 variant (Figure 2B). Thus, the Q688 variant behaves as
a gain of function.
Molecular Modeling Suggests a Stabilizing Influence of
the Q688 Variant
We built a 3Dmodel to analyze the impact of the Q688 variant on
the structure of the SPG7/AFG3L2 heterohexamer (Figure 3C).
Salt bridge formation between residues at the central pore of
the heterohexamer could stabilize the complex. The R688 resi-
due in the common form of SPG7 directly faces K415 in
AFG3L2, and positive charge repulsion between these two res-
idues is likely attenuated by the spatially proximal E691 of
AFG3L2 forming a salt bridge with K415. In contrast, Q688 of
the variant makes a salt bridge both with K415 and E691, pre-
sumably stabilizing the heterohexamer that could alter the
mechanism by which the protease pore functions. To test
this hypothesis, we performed native gel electrophoresis (BN-
PAGE) and found that cells expressing the Q688 variant had
higher levels of SPG7-containing mAAA protease complexes,
consistent with increased stabilization by the Q688 variant
(Figure 2D).
The Q688 SPG7 Variant Increases ATP Production
Because the SPG7/AFG3L2 mAAA protease requires ATP for its
activity (Augustin et al., 2009; Langer, 2000) and participates in(G) Mitochondria from stably transformed HEK293 cells expressing the Q688 v
expressing the common allele (R688) or nontransfected cells (NT) (n = 4). AFG3L2
TOM20 was used as a mitochondrial loading control protein marker. Overexpres
isoforms (Figure S1).mitochondrial ribosome assembly (Almajan et al., 2012; Nolden
et al., 2005) and the degradation of inner membrane proteins
(Maltecca and Casari, 2010), we asked whether increased pro-
cessing and production of the active form of SPG7 by the
Q688 variant would increase energy demands and affect ATP
production. We performed immunoblot analysis of phosphory-
lated AMPK (phospho-AMPK) from the mitochondrial extracts
of genotyped PBMCs that were used in Figure 1D as well as
whole-cell extracts of stably transfected cells. AMPK is a cellular
energy sensor that is phosphorylated when ATP levels are inad-
equate and the ratio of ATP to ADP is low (Hardie, 2003). We
observed markedly reduced levels of phospho-AMPK in PBMCs
from homozygous carriers of the Q688 variant (Figure 3A). Simi-
larly, cells overexpressing both the common and the variant
Q688 forms of SPG7 (Figure 3A) had reduced levels of
phospho-AMPK, indicating that these cells have increased
ATP production. Althoughwe could notmeasure ATP production
in the frozen banked PBMCs, consistent with the phospho-
AMPK results, we found elevated ATP synthesis in mitochondria
isolated from stable HEK293 cells overexpressing the common
form of SPG7, and even more so the Q688 variant, suggesting
increased respiratory activity (Figure 3C). Similarly, mitochondria
from primary human umbilical vein endothelial cells (HUVECs)
transduced with lentiviral vector expressing the Q688 SPG7
variant also had elevated ATP production (Figure 3D), although
HUVECs transduced with the common form (R688) did not
have increased ATP production, despite expressing similar
levels of SPG7 (data not shown). Uninfected HUVECs were
homozygous for the common allele.
The Q688 SPG7 Variant Alters the Stoichiometry of
Components of the ETC and Proton Leak fromFatty Acid
Oxidation
Themitochondrial ribosome protein Mrpl32 is required for the de
novo synthesis of mitochondrially encoded respiratory chain
subunits and is a natural target of the mAAA protease (Almajan
et al., 2012; Nolden et al., 2005). Upon expression in yeast,
loss-of-function mutations in AFG3L2 impair processing of the
Mrpl32 precursor leading to respiratory chain deficiencies
(Bonn et al., 2010; Di Bella et al., 2010).
Almajan et al. observed decreased levels of mature Mrpl32 in
the absence of the m-AAA protease in AFG3L2-deficient cells
(Almajan et al., 2012). The increased production of the active
form of SPG7 by the Q688 variant was expected to have the
opposite effect. Indeed, we found that Mrpl32 processing is
enhanced in PBMCs homozygous for the Q688 allele (Figure 3E)
as well as in cells expressing the Q688 variant (Figure 3F), indi-
cating increased activity of the m-AAA protease. Surprisingly,
although the mitochondrially encoded cytochrome c oxidase 1
(COX1) and COX3, as well as the nuclear-encoded COX4, sub-
units of complex IV were elevated in cells overexpressing the
Q688 variant, COX2 levels were not affected (Figures 3E and
3F). Furthermore, despite COX2 levels not being increased,ariant show increased processing to mature SPG7 compared to cells stably
levels are increased in cells expressing the variant, as were the levels of PRDX3.
sion of SPG7 (mature and precursor) was not different for the Q688 and R688
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Figure 2. The SPG7 Q688 Variant Rescues
Loss-of-Function AFG3L2 Mutants in Yeast
(A) Silencing of AFG3L2 prevents processing of the
common form of SPG7, but not the Q688 variant,
in whole-cell extracts. Quantification is shown of
mature SPG7 as a percentage of total SPG7 (n = 2
experiments).
(B) Complementation studies in S. cerevisiae
tested for the ability of the Q688 variant (R688Q) to
rescue mutant forms of AFG3L2. Serial dilutions
of exponentially growing yeast cultures spotted
on plates show oxidative growth phenotype of
yta10Dyta12D cells (D D) expressing normal and
mutant human AFG3L2. Respiratory competence
is deduced by the ability to grow on 2% glycerol
(YPG), a nonfermentable carbon source. The pro-
tease-deficient variant of AFG3L2 (E575Q) was
partially rescued by the Q688 variant, but the in-
activating variant (E691K) was restored to the
same extent as cells overexpressing the WT
AFG3L2. In contrast, the common form of SPG7
did not rescue the inactivating variant of AFG3L2
(n = 2 experiments, in duplicate).
(C) Model of an SPG7 Q688 and AFG3L2 hetero-
hexamer suggests increased stability. Using the
structure of the Thermus thermophilus AAA pro-
tease FtsH as a template (Suno et al., 2006), we
modeled the effect of the Q688 variant on a het-
erohexameric complex with AFG3L2. An enlarged
view of the surface representation of the protease
face of the AFG3L2/SPG7 heterohexamer (dashed
white circle) shows an enlarged wire-frame model
of the protease pore. In the common form of SPG7,
R688 phases directly K415, a conserved positively
charged residue present in AFG3L2, whereas the
Q688 residue of the variant SPG7 can form a salt
bridge directly with K415.
(D) BN-PAGE immunoblot analysis of supramo-
lecular assembly of SPG7. Blue native electro-
phoresis of whole-cell extracts from HEK293 cells
stably expressing R688 or Q688 showed higher
levels of SPG7-containing complexes (1 MDa) in
cells expressing the Q688 variant compared to
R688-expressing cells (n = 4). Medium-chain acyl-
CoA dehydrogenase (MCAD) was used as BN-
PAGE loading control.COX activity was elevated in isolated mitochondria expressing
the Q688 variant, but not the common form of SPG7 (Figure 3G).
Electronmicroscopy revealed an increased number ofmitochon-838 Cell Reports 7, 834–847, May 8, 2014 ª2014 The Authorsdria in cells expressing the Q688 variant
(Figure 3H), providing an explanation for
elevated ATP production in these cells.
The effect of overexpressing the com-
mon and Q688 variant of SPG7 on bioen-
ergetics was further assessed in living
cells using a Seahorse analyzer. Cells
were fed with glutamine and pyruvate,
substrates of the Krebs cycle that
generates reduced nicotinamide adenine
dinucleotide required for oxidative phos-
phorylation and ATP production. Cellsoverexpressing either the common or variant Q688 SPG7 had
an increased resting oxygen consumption rate (OCR) in compar-
ison to nontransfected cells (Figure 4A) and increased
Figure 3. The SPG7 Q688 Variant Alters Mitochondrial Bioenergetics
(A and B) Immunoblot analysis showed that phospho-AMPK levels are markedly lower in whole-cell extracts of PBMCs from patients with CAD homozygous for
the Q688 variant (A) and in HEK293 cells stably expressing the Q688 variant (B) (n = 3).
(C and D) ATP synthesis was elevated in stably transfected HEK293 cells (C) and in lentiviral-transduced HUVECs (D) expressing Q688. ATP synthesis was
measured by a luciferase assay using isolated mitochondria (n = 6). *p < 0.001 compared to control; **p < 0.001 compared to R688.
(E and F) Stoichiometry of complex IV subunits is altered in mitochondrial extracts of PBMCs homozygous for the Q688 variant (E) or in whole-cell extracts of
HEK293 cells overexpressing Q688 (F). Levels of Mrpl32 were increased in cells expressing the Q688 variant, indicating increased processing of this ribosomal
subunit of mitochondria. However, expression of COX2 was not coordinately upregulated with COX1, COX3, and COX4 in cells expressing the Q688 variant.
GAPDH was used as a loading control. Proteins were quantified by densitometry (n = 3). *p < 0.05.
(G) COX activity was elevated in isolated mitochondria of HEK293 cells overexpressing the Q688 variant (n = 3 experiments).
(H) Electron micrographs revealed increased numbers of mitochondria in cells expressing the Q688 variant compared to NT cells or cells expressing the common
form of SPG7. Scale bars, 2 mm. Quantification of mitochondrial density (mitochondria/mm2 of cytoplasm) was obtained by counting mitochondria (white arrows)
from ten individual cells per genotype. Mean ± SEM. *p < 0.001.
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Figure 4. Effect of SPG7 Q688 Variant on
Cellular Bioenergetics Measured in Living
Cells
Cells were either fed pyruvate (A–C) or oleate (D and
E) as substrates.
(A) Resting OCR is elevated in cells expressing the
common and variant (Q688) form of SPG7 when fed
the TCA cycle substrate pyruvate (n = 4).
(B) Cells expressing the Q688 variant fed pyruvate
show an elevated contribution of resting respiration
to the aerobic synthesis of ATP (n = 4) (see Figure S1
for details).
(C) Proton leak-dependent OCR was not affected
by overexpression of the SPG7 common or variant
forms.
(D) A higher-percent contribution of resting OCR to
ATP synthesis was observed in cells expressing the
Q688 variant when fed oleate (n = 4).
(E) The contribution of resting respiration to
aerobic synthesis of ATP was suppressed by
overexpression of the R688 form of SPG7 but was
elevated by overexpression of the Q688 variant.
(F) Proton leak-dependent OCR in cells expressing
the Q688 variant was suppressed (n = 4) (see Fig-
ure S1 for details).
In (A)–(F), mean ± SEM.
(G) Cells expressing the Q688 variant accumulate
less fatty acid, as indicated by Nile red fluores-
cence, after 24 hr loadingwith 100mMoleate. Scale
bar, 50 mm.
*p < 0.05; **p < 0.01.carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP)-
stimulated OCR (Figure S3B). Of note, subtracting the proton
leak-dependent respiration from resting respiration reveals that
cellular respiration associated with ATP synthesis is higher in
Q688-expressing cells (Figure S3C). These results agree with
the increased ATP synthesis measured in isolated mitochondria.
We next determined the contribution of resting respiration
toward aerobic ATP synthesis, as an index of energy efficiency,
and found that a higher proportion of resting respiration was
used to support aerobic ATP synthesis in cells expressing the
Q688 variant (Figure 4B). No difference in proton leak-dependent
OCR or glycolytic rate was observed between nontransfected
and stably transfected cells expressing either the common or
Q688 form of SPG7 (Figure 4C). Also, it is important to note
that no difference in resting, proton leak-dependent, or FCCP-
stimulated respiration was observed in these cells provided
with the standard Seahorse glucose-supplemented incubation
medium (data not shown). These results indicate that overex-
pression of the common or the Q688 variant SPG7 does not
cause cell stress (Bravo et al., 2011).
Next, we measured the bioenergetics of cells supplied with
oleate, a nonfermentable carbon source that requires oxidative
metabolism at the mitochondrial matrix (Figures 4D–4F). Intrigu-
ingly, no difference in resting respiration was observed between
nontransfected cells and cells expressing either the R688 or
Q688 variant (Figure 4D). FCCP-stimulated respiration was lower840 Cell Reports 7, 834–847, May 8, 2014 ª2014 The Authorsin cells expressing the R688 and the Q688 form of SPG7 (Fig-
ure S4B), whereas no difference in glycolytic rate was observed
(Figure S4C). However, cells overexpressing the Q688 variant
of SPG7 contributed a larger proportion of oxygen consumption
to produce ATP from oleate (Figure 4E). Consistent with
this finding, proton leak-dependent respiration was markedly
reduced for the Q688-expressing cells (Figure 4F). Because pro-
ton leak buffers cellular ROS (Brookes, 2005), this suggests
reduced ROS-buffering capacity with oleate. Next, we loaded
cells with oleate and observed fewer fat droplets in cells ex-
pressing the Q688 variant (Figure 4G). Together, these results
show higher fatty acid consumption by b-oxidation and reduced
proton leak in cells expressing the Q688 variant, predicting
higher ROS production in these cells.
The Q688 SPG7 Variant Increases mROS Levels
Altered ETC protein stoichiometry has been associated with
elevated ROS release from mitochondria (Sohal et al., 2008).
Furthermore, cells expressing the Q688 variant contributed a
larger proportion of mitochondrial respiration to fatty acid oxida-
tion, a known source of ROS (Rosca et al., 2012). We then visu-
alized mROS production using the vital dye MitoSOX Red by
fluorescence microscopy and found that HEK293 cells express-
ing the Q688 variant had markedly elevated ROS production
compared to those expressing the common allele (Figure 5A).
In addition, we also used the conversion of dihydroethidium to
ethidium that accumulates in the nucleus of stable HEK293 cells
actively producing ROS, and confocal time-lapse fluorescent im-
age reconstructions further confirmed that ROS production was
mitochondrial by the colocalization of hydroethidium (Het; Fig-
ure 5A, red) with MitoTracker (Figure 5A, green) (see Movies S1
and S2). ROS levels were also quantified by a colorimetric assay
and found to be elevated in stable HEK293 cells (Figure 5B) and
in HUVECs transduced with lentiviral vector (Figure 5C) express-
ing theQ688 variant. Elevated levels of ROS-scavenging enzyme
PRDX3 in PBMCs from patients with CAD homozygous for the
Q688 allele (Figure 3E) and inmitochondria from cells expressing
the Q688 variant (Figure 1G) were consistent with increased
mROS production. Because mitochondrial membrane potential
drives mROS production (Echtay et al., 2002), we measured
mitochondrial membrane potential using the fluorescent dye tet-
ramethylrhodamine ethyl ester (TMRE) and found that it was
elevated in cells expressing the Q688 variant (Figure 5D). ROS
production activates endothelial nitric oxide synthase (eNOS)
activity, in part by the dephosphorylation of a constitutively
phosphorylated inhibitory threonine at position 495 (peNOS-
Thr495) (Thomas et al., 2002). PBMCs homozygous for the
Q688 variant had markedly reduced peNOS-Thr495 levels (Fig-
ure 5E). A similar result was observed in HUVECS transduced
with lentiviral vector expressing the Q688 variant (Figure S5).
eNOS activation promotes mitochondrial biogenesis (Nisoli
et al., 2004), and the levels of themitochondrial transcription fac-
tor A (TFAM) were elevated in PBMCs homozygous for the R688
SPG7 variant (Figure 5E), consistent with increased mitochon-
drial density observed by electron microscopy in cells overex-
pressing the R688 variant (Figure 3H). Consistent with the re-
ported effects of mROS and TFAM to stabilize hypoxia-
inducible factor 1a (HIF1a) (Bell et al., 2007), we found that cells
expressing the Q688 variant had elevated basal HIF1a levels and
increased activation of HIF1a in response to hypoxia (Figure 5F).
The Q688 SPG7 Variant Increases Cell Proliferation
Increased mROS production promotes cell proliferation (For-
mentini et al., 2012), a hallmark of atherosclerotic lesions (Gue-
vara et al., 1999). Given that HEK293 cells expressing the
Q688 variant had increased ROS production, we tested whether
cell proliferation was also increased. Flow cytometry after bro-
modeoxyuridine (BrdU) incorporation showed that HEK293 cells
expressing the Q688 variant had a 4-fold increase in cell prolifer-
ation (Figure 5G). Markers of cellular proliferation, like the prolif-
erating cell nuclear antigen (PCNA), cyclin E, and cyclin D, and
the level of phosphorylated retinoblastoma (pRB) were all
elevated, whereas the cyclin-dependent kinase inhibitors p27
and p21 were suppressed in these cells (Figure 5H). Addition
of the ROS scavengers N-acetyl cysteine (NAC) and Tiron
blunted the elevation of PCNA and cyclin E levels (Figure 5I).
Thus, these results are consistent with the notion that mROS
production controls cellular proliferation (Formentini et al., 2012).
Forskolin Blocks Processing of the R688 SPG7 but Not
the Q688 Variant
Next, we asked whether the degree of SPG7 processing might
be regulated by the metabolic state, like fasting, when protein
kinase A (PKA) is activated (Ritter and Hall, 2009). Activation ofPKA by Forskolin in vitro markedly inhibited processing of
the common form of SPG7 but had little effect on processing
of the Q688 variant (Figure 6A). This indicates that processing
of SPG7 is dynamically regulated. To identify a mechanism
whereby PKA activation might control SPG7 processing by
AFG3L2, we consulted the PhosphoSitePlus databases of
curated tandem mass spectrometry sequences (http://www.
phosphosite.org/). AFG3L2 contains 3 phosphorylated residues:
Y179 (identified in 12 independent reports) in the Fts homology
external (FtsH-ext) domain facing the mitochondrial intermem-
brane space, and T560 (1 report) and S634 (2 reports) on the
matrix side (Figure 6B).
PKA activates an unknown tyrosine kinase in the intermem-
brane space (Lee et al., 2005; Miyazaki et al., 2003). A phospho-
peptide of SPG7 phosphorylated at Y195 has been deposited in
the PhosphoSitePlus database, but we were unable to confirm
this finding by immunoprecipitation or mass spectrometry
(data not shown). We therefore examined the possibility that
phosphorylation of AFG3L2 regulates SPG7 processing. Immu-
noprecipitation of AFG3L2 followed by immunoblot analysis
using phosphorylated residue-specific antibodies revealed that
Forskolin markedly increased phosphorylation of tyrosine resi-
dues (Figure 6C). To test whether Y179 of AFG3L2 affects pro-
cessing of SPG7, we used site-directed mutagenesis to convert
this residue to aspartic acid (Y > D, amutation bearing a negative
charge that mimics phosphorylation) or to phenylalanine (Y > F, a
residue that cannot be phosphorylated) and tested the effect of
overexpression of wild-type (WT) and mutant c-myc-tagged
AFG3L2 proteins on endogenous SPG7 processing (Figure 6D).
The AFG3L2 Y179D mutation caused accumulation of the inter-
mediate form of SPG7 compared to the WT form of AFG3L2.
In contrast, the phosphorylation-dead AFG3L2 mutant Y179F
stimulated SPG7 processing. Processing of AFG3L2 was also
affected similarly by thesemutations, suggesting that phosphor-
ylation of Y179 affects processing of both AFG3L2 and SPG7.
In Figure 7, we propose a model whereby Y179 phosphoryla-
tion of AFG3L2 controls processing of the common formof SPG7
(as well as AFG3L2) to regulate mitochondrial bioenergetics and
mROS production. The Q688 variant appears to escape the
AFG3L2-dependent control mechanism because it is efficiently
processed independently of AFG3L2 phosphorylation at Y179
and maintains mitochondria in an energetically activated state.
DISCUSSION
We have characterized Q866 as a gain-of-function variant of
SPG7 that causes an increased activity of SPG7-containing
mAAA proteases. The SPG7 Q866 variant is efficiently pro-
cessed independent of phosphorylation of AFG3L2 at Y179,
which inhibits processing of SPG7. This increases mROS pro-
duction, mitochondrial biogenesis, and cellular proliferation.
Our data showed that the Q688 variant of SPG7 is a gain of func-
tion that rescues a dominant-negative form of AFG3L2 (E691K)
associated with SCA28. It will be interesting to determine
whether individuals who carry the SCA28 mutation of AFG3L2
(E691K) (Di Bella et al., 2010) and also carry the Q688 variant
have an attenuated phenotype relative to individuals homozy-
gous for the common form of SPG7. This could account for theCell Reports 7, 834–847, May 8, 2014 ª2014 The Authors 841
Figure 5. The SPG7 Q688 Variant Increases mROS Production and Cellular Proliferation
(A) mROS was visualized using MitoSOX (red), and mitochondria were visualized using MitoTracker (green). Scale bar, 20 mm.
(B and C) Intracellular ROS measured by DCF fluorescence were highly elevated in HEK293 cells (B) as well as in lentiviral vector-transduced HUVECs (C)
expressing the Q688 variant (n = 3 experiments).
(legend continued on next page)
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Figure 6. SPG7 Processing Is Controlled by
AFG3L2 Phosphorylation
(A) Forskolin (FSK) blocks processing of the R688
common form but not the Q688 variant of SPG7.
Quantitation of immunoblots (10% acrylamide)
showed a significant inhibition of R688 SPG7
processing (n = 3 experiments). Mean ± SEM.
(B) AFG3L2 is phosphorylated at three resi-
dues (Y179, T560, and S634), as reported by
multiple mass spectrometry studies (http://www.
phosphosite.org/).
(C) Forskolin increases tyrosine phosphorylation
of AFG3L2. Immunoblots (10% acrylamide) of
immunoprecipitated AFG3L2 protein from whole-
cell extracts were probed with phosphotyrosine,
phosphothreonine, and phosphoserine antibodies.
GAPDH antibody confirmed specificity of AFG3L2
immunoprecipitation (Figure S6).
(D) Tyrosine 179 of AFG3L2 regulates SPG7
processing. Site-directed mutagenesis of c-my-
taggedWT AFG3L2 (WT) converted tyrosine 179 to
a pseudophosphorylated aspartic acid (Y > D) or to
a nonphosphorylatable phenylalanine (Y > F).
Immunoblots (6% acrylamide) of whole-cell ex-
tracts were probed with antibodies to SPG7,
c-myc (to detect overexpressed AFG3L2), and
GAPDH to control for loading.variable penetrance reported for this dominant form of hereditary
ataxia (Cagnoli et al., 2006).
The association of the Q688 allele with CAD risk at a level that
does not reach genome-wide significance (p = 3.74 3 105) is
indicative of the pleiotropic effects of this allele. Indeed, a similar
association was reported with the risk for type 2 diabetes in the
DIAGRAMconsortium (stage 2, OR = 1.05 [1.02–1.08], p = 0.003;
n = 75,063) (Morris et al., 2012). Mitochondrial dysfunction and
mROS production have been implicated in T2DM (Lowell and
Shulman, 2005). A limitation of our study is the lack of data on
T2DM in the CARDIoGRAM cohorts. However, because dia-
betes was an exclusion criterion in the OHGS, the association
with CAD and T2DM is likely to be independent.
A recent pharmacogenetic study found that patients with
prostate cancer who carry the Q688 variant are more resistant
to the toxic effects of anticancer drugs (Deeken et al., 2010). It
is likely that the increased ability to detoxify xenobiotic com-
pounds is a direct effect of the Q688 variant. This could explain
how this allele has become fixed in the human population. Genes
involved in detoxifying xenobiotics evolve more rapidly (Green-
berg et al., 2008), presumably because they offer a strong selec-(D)Mitochondrial membrane potential measured using the TMRE fluorescent prob
experiments).
In (B)–(D), mean ± SEM.
(E) Immunoblot analysis of whole-cell extracts shows that PBMCs homozygous f
threonine 495 (peNOS-Thr495), and increased levels of TFAM.
(F) Basal and hypoxia-induced (1.5% O2 for 4 hr) HIF1a levels are higher in cells
(G) FACS analysis of BrdU incorporation of synchronized stable HEK293 cells
experiments).
(H) Immunoblot analysis revealed elevated levels of cell proliferation markers (PC
(p27 and p21) in whole-cell extracts of HEK293 cells stably expressing the Q688
(I) ROS scavengers NAC (10 mM) or Tiron (10 mM) restored PCNA and cyclin E ltive advantage. The Q688 allele shows a similar frequency in
Asians as in Europeans (11%–16%) but is rare in black Africans.
Although a variant that protects against toxic xenobiotic com-
pounds would confer immediate advantage, the long-term
consequence of this gain of protease function may be to in-
crease susceptibility to diseases of aging like CAD and T2DM.
A key finding of our study is that cleavage and activation of
SPG7 are regulated processes that can be inhibited by a PKA-
like activity. The ability to inhibit the mAAA protease by blocking
the cleavage and activation of SPG7 allows cells to regulate
mitochondrial protein synthesis and degradation to meet their
metabolic needs. Because PKA is a serine/threonine kinase,
our data suggest that PKA indirectly inhibits SPG7 processing
by activating a tyrosine kinase in the intermembrane space
that phosphorylates AFG3L2 at tyrosine 179. Tyrosine kinase
activity in mitochondria is located in the intermembrane space
(Salvi et al., 2002), and several studies have shown that mito-
chondrial tyrosine kinase activity modulates cellular metabolism
(Hitosugi et al., 2011; Lee et al., 2005; Miyazaki et al., 2003).
Although the PhosphoSitePlus repository documents phosphor-
ylation of Y195 in SPG7, we were unable to confirm this finding,e showed highermembrane potential in cells expressing theQ688 variant (n = 4
or the Q688 variant have activated eNOS, as revealed by dephosphorylation of
expressing the Q688 variant (n = 4 experiments).
showed increased proliferation of cells expressing the Q688 variant (n = 2
NA, CyclinE, Cyclin D, and p-RB) and reduced levels of cell-cycle suppressors
variant (n = 3 experiments). GAPDH verified protein loading.
evels (n = 3 experiments).
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Figure 7. Model of SPG7 Processing
SPG7 preprotein is imported from the cytosol through the intermembrane (IM)
space to the mitochondrial matrix, where the signal peptide is cleaved by the
MPP. SPG7, like its partner AFG3L2, is somehow anchored through two
transmembrane (TM) domains to the inner mitochondrial membrane, with the
protease domain facing the matrix. Upon coassembly, tyrosine phosphoryla-
tion of AFG3L2 prevents processing of SPG7. Mature SPG7 protein is pro-
cessed when AFG3L2 is not phosphorylated. The Q688 variant escapes this
regulatory process.suggesting that regulation of SPG7 processing takes place
largely through its interaction with AFG3L2. Consistent with
this notion, we found that overexpression of a mutant form of
AFG3L2 that cannot be phosphorylated at Y179 (Y179F) pro-
moted SPG7 (and AFG3L2) processing. It will be important in
future studies to identify the tyrosine kinase and phosphatase
that regulate AFG3L2 Y179 phosphorylation and SPG7 process-
ing. The Q688 variant is insensitive to AFG3L2-mediated regula-
tion; this could result from its stabilized interaction with AFG3L2
at the protease pore complex, or if this variant of SPG7 is inde-
pendent of AFG3L2 (i.e., autocatalytic).
The presence of a constitutively activated mAAA protease in
cells expressing the Q688 variant of SPG7 likely leads to an
altered stoichiometry of ETC complexes and increased mROS
production. Complex IV stoichiometry was similarly altered in
PBMCs from patients with CAD homozygous for the Q688
allele as in HEK293 cells overexpressing the Q688 variant, indi-
cating that this is a natural and direct consequence of the
Q688 allele. Cellular bioenergetics was affected differently by
overexpression of the R688 and Q688 variant of SPG7, in
particular in the presence of oleate as a substrate of b-oxida-
tion, a known source of mROS (Rosca et al., 2012). We
observed that cells expressing the Q688 variant required a
larger proportion of oxygen consumption to produce ATP
from oleate and accumulated less oleate in lipid droplets,
consistent with increased fatty acid utilization. In addition,
these cells displayed reduced proton leak when fed oleate,
consistent with reduced ROS-buffering capacity accounting
for elevated mROS levels.
Mitochondrial biogenesis was increased in cells expressing
the Q688 variant. The mitochondrial count was elevated in elec-
tronmicrographs, and expression of the TFAMwas also elevated
in these cells. We observed that expression of Tom20, the mito-
chondrial translocase of the outer membrane, was not changed844 Cell Reports 7, 834–847, May 8, 2014 ª2014 The Authorsdespite increased mitochondrial biogenesis. Of note, during
muscle differentiation when mitochondrial biogenesis is acti-
vated, Tom20 levels remain relatively unchanged (Grey et al.,
2000). Thus, increased mitochondrial biogenesis is not neces-
sarily accompanied by increased Tom20 expression.
Increased mROS production increases cell proliferation (For-
mentini et al., 2012), and depletion of ROS by NAC induces
cell-cycle arrest (Kim et al., 2001). We observed increased prolif-
eration of cells expressing theQ688 variant, and the upregulation
of cyclin E and PCNA was reversed by NAC or Tiron, providing
direct evidence that mROS drives proliferation in these cells.
The altered bioenergetics of mitochondria expressing Q688, in
particular the reduced proton efflux when utilizing oleate as a
substrate of fatty acid oxidation, is consistent with a reduced
ability to buffer ROS, leading to elevated ROS production.
Furthermore, elevated mROS production associated with fatty
acid oxidation (Yamagishi et al., 2001), increased HIF1a and its
associated effect on inflammation (Bartels et al., 2013), and
increased cell proliferation are all conditions that would promote
coronary atherosclerosis.
The innate immune response is also tied to mROS produc-
tion. Importantly, the bactericidal activity of macrophages is
activated by Toll-like receptors 1, 2, and 4 through elevated
mROS production (West et al., 2011). CAD has long been
suspected of being linked to bacterial infections and inflam-
mation (Danesh et al., 1997). The Q688 variant, through its
effect on elevating mROS production, may promote innate
immunity, but at the cost of increased inflammation that con-
tributes to CAD. That PBMCs from patients with CAD homozy-
gous for the Q688 variant showed similar elevations in PRDX3
as seen in cells overexpressing the Q688 variant is consistent
with the notion that this allele might augment the inflammatory
response.
To date, GWASs have identified more than 40 genetic variants
contributing to the risk for CAD (Roberts and Stewart, 2012) but
account for only 10%of the CAD heritability. This is due in part to
the limited power of the GWAS to discover CAD genetic risk var-
iants that are pleiotropic (Manolio et al., 2009). Pleiotropy occurs
when a genetic factor influences more than one physiological
trait. Thus, if individuals who have these traits are included in
the control group, this would prevent pleiotropic genetic variants
that contribute to CAD risk from reaching a level of stringent
genome-wide significance (p < 5 3 108). Our discovery and
functional characterization of the Q688 SPG7 variant as a poten-
tial risk factor for CAD and its pleiotropic effects support the
notion that much of the missing heritability contributing to the
risk for CAD is carried by similar functionally important but pleio-
tropic alleles.
EXPERIMENTAL PROCEDURES
GWASs
All participants gave written informed consent according to study protocols
approved for each of the 12 GWASs as described extensively in the
CARDIoGRAM study by Schunkert et al. (2011) and in the Supplemental
Experimental Procedures.
Cell Culture, Plasmid Constructs, and Transfection
Details are provided in the Supplemental Experimental Procedures.
Yeast Complementation Assay
Studies in S. cerevisiaewere carried out as described previously by Bonn et al.
(2010) and Koppen et al. (2007) and as detailed in Supplemental Experimental
Procedures.
Determination of Mitochondrial H+-ATPase Activity
Mitochondria and cytosol were isolated as described by Schauss et al. (2010).
Mitochondrial H+-ATPase activity was measured by fluorescence biolumines-
cence (A22066; Molecular Probes), as described by Qian et al. (2004) and as
detailed in the Supplemental Experimental Procedures.
In Situ Measurement of Cellular Bioenergetics
Mitochondrial bioenergetics and glycolytic flux were tested in intact cells using
the Seahorse XF24 Extracellular Flux Analyzer (Seahorse Bioscience, North
Billerica), as described previously (Mailloux et al., 2011) and as detailed in
the Supplemental Experimental Procedures.
Immunoblot and Immunoprecipitation
Immunoblot and immunoprecipitation protocols and antibodies are described
in detail in the Supplemental Experimental Procedures.
Structural Modeling of AFG3L2 and SPG7, Q688, Heterohexamer
Molecular models of AFG3L2 and SPG7 were built as described previously
by Di Bella et al. (2010) and in detail in the Supplemental Experimental
Procedures.
Intracellular ROS Measurement
The OxiSelect ROS Assay Kit (STA-342; Cell Biolabs) was used to assay
ROS activity in HEK293 cells. This is a cell-based assay for measuring
activity of ROS using a cell-permeable fluorogenic probe 20, 70-dichlorodihy-
drofluorescein (DCFH) diacetate (DCFH-DA) that is deacetylated by cellular
esterases to nonfluorescent DCFH once in the cells. DCFH is rapidly
oxidized to highly fluorescent 20, 70-dichlorodihydrofluorescein (DCF) by
ROS, and fluorescence intensity is proportional to the ROS levels within
the cytosol.
Confocal Live Imaging and Videos
Details are provided in the Supplemental Experimental Procedures.
Electron Micrography
Cells were cultured on plastic coverslips, washed in PBS, fixed in 1.6% glutar-
aldehyde, and were embedded in LR white (Marivac). Thin sections were cut
with a Leica Ultracut E ultramicrotome and counterstained with lead citrate
and uranyl acetate. Digital images were taken using a JEOL 1230 transmission
electron microscope at 60 kV adapted with a 23 2 K bottom-mount CCD dig-
ital camera (Hamamatsu) and AMT software.
BrdU Staining and Fluorescence-Activated Cell Sorting Analysis
Details are provided in the Supplemental Experimental Procedures.
Mass Spectrometry
Details are provided in the Supplemental Experimental Procedures.
Measurement of Mitochondrial Membrane Potential
The fluorescent probe TMRE (Abcam; ab-113852) was used to measure mito-
chondrial membrane potential in cells expressing R688 or Q688, as described
previously by McClintock et al. (2002).
Cytochrome Oxidase Assay
The determination of COX activity in isolated mitochondria was carried out
using the Cytochrome c Oxidase Assay Kit according to the manufacturer’s
protocol (Sigma-Aldrich).
Oleate Loading Assay
HEK293 cells were cultured in modified Eagle’s medium containing 10%
fetal bovine serum supplemented with 100 mM oleate for 24 hr. Cells were
stained with Nile red (Greenspan et al., 1985), and lipid droplets werevisualized by fluorescence using a Zeiss AxioImager.Z1 fluorescence
microscope.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.03.051.
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